CN1025908C - 巴豆抗癌药的制备方法 - Google Patents
巴豆抗癌药的制备方法 Download PDFInfo
- Publication number
- CN1025908C CN1025908C CN 89107860 CN89107860A CN1025908C CN 1025908 C CN1025908 C CN 1025908C CN 89107860 CN89107860 CN 89107860 CN 89107860 A CN89107860 A CN 89107860A CN 1025908 C CN1025908 C CN 1025908C
- Authority
- CN
- China
- Prior art keywords
- fructus crotonis
- filter
- extractum
- water
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 241001448862 Croton Species 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 9
- 238000002347 injection Methods 0.000 claims abstract description 11
- 239000007924 injection Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000006184 cosolvent Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 238000003810 ethyl acetate extraction Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 4
- 206010017758 gastric cancer Diseases 0.000 abstract description 4
- 201000011549 stomach cancer Diseases 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 239000003005 anticarcinogenic agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000005325 percolation Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- MIKUYHXYGGJMLM-UUOKFMHZSA-N Crotonoside Chemical compound C1=NC2=C(N)NC(=O)N=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MIKUYHXYGGJMLM-UUOKFMHZSA-N 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000002316 fumigant Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical group COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种巴豆抗癌药的制备方法,它是以巴豆为原料,经提取其中有效抗癌成分,消除有毒成份配制而成。该药有针剂和口服剂两种剂型,具有疗效好,毒副作用小,用药安全等特点,其生产工艺简单、成本低、无污染,可用于多种癌症的治疗,尤其适用于胃癌,有效率达72.8%。
Description
本发明属于抗癌药的制备方法。
癌症是严重危胁人类生命健康的恶性疾病,被称为不治之症。目前人类已经掌握了一些治疗癌症的方法,而且仍在不断研究探索新的治疗方法。近四十年来癌症的药物治疗已经有了很大发展,而且正在从姑息性治疗向根治性治疗过渡。但现有的各种抗癌药都存在许多不足,如疗效低,毒性大,用药后对人体的正常机能有较大损害。抗癌药的生产工艺比较复杂,成本高,对环境污染严重,不适合大规模生产。近些年,人们发现一些中药对某些癌症有一定治疗效果,应用中医中药治疗癌症受到了人们的普遍关注,本发明就是以中药材巴豆为原料制成的一种新抗癌药。
巴豆系大戟科植物巴豆树(Croton LigliumL)的干燥成熟的种子,中医药典记载,巴豆性热、味辛、大毒。功能:峻泻寒积,逐水消肿。用于寒积停滞、胸腹胀痛、水肿、喉风、喉辛等症。关于巴豆的化学成分和生理活性作用的研究,较早的报导是在1912年,Itzkowitsch认为巴豆油的毒性刺激作用,是因为含巴豆毒素(Crotoni),1930年Bohm等从油中分离出巴豆树脂,并从中分离出一种萜醇-大戟二萜醇(Phorbol),1932年分离出巴豆甙(Crotouoside)。随后的几十年中人们不断对巴豆做进一步研究,已证明巴豆的主要成份为巴豆油、巴豆甙、生物碱、β-谷甾醇等,其中巴豆油等为致癌成份,为大戟二萜醇的衍生物。在我国民间也流传有用巴豆治疗肿瘤的方法,如巴豆和砒霜制成薰剂治疗食道癌等。
本发明的目的是以中医药学理论为指导、利用巴豆为原料,研究生产一种疗效好、毒副作用小、用药安全可靠的新型抗癌药,该药对多种癌症均有一定疗效。本发明的制备方法生产工艺简单,成本低,无污染。
本发明是一种以巴豆为原料制成的715巴豆抗癌药及其制备方法,其特征在于该药的主要成份为巴豆总生物碱;制备方法有两种,分别适用于制备针剂和口服剂。其特征在于方法一是由下列步骤组成:
(1)将巴豆粉碎,置容器中蒸制(常压蒸馏);
(2)取蒸制液,加入20~40%(体积比)的溶剂提取至少二次;
(3)回收溶剂得浸膏,再加入适量助溶剂搅匀;
(4)加注射用水至足量,摇匀、过滤,得无色透明溶液。
该方法适合制备肌注针剂,所说的溶剂为酯类有机溶剂、最好采用乙酸乙酯;助溶剂为吐温-80。其工艺流程见图一。
图一为方法一的工艺流程图
图二为方法二的工艺流程图
方法二是由下列步骤组成:
(1)将巴豆粉碎研制,置有机溶剂Ⅰ中浸泡24~72小时,过滤、干燥得脱脂巴豆粉;
(2)将脱脂巴豆粉置有机溶剂Ⅱ中浸泡24~72小时,过滤,得棕黄色溶液;
(3)回收溶剂得棕黄色浸膏;
(4)将上述浸膏溶于水,过滤,再加入适量氯
仿,使之充分混合,分离出水溶液,经加热浓缩,得纯净的巴豆浸膏;
(5)将上述浸膏溶解于水,制成水溶液,过滤,即可用于配制口服剂。
有机溶剂Ⅰ为醚,最好为石油醚,有机溶剂Ⅱ为醇,最好为乙醇。其工艺流程见图二
本发明是在民间验方的基础上,经不断研究开发而成。经分析,其中抗癌活性成份为巴豆总生物碱。本发明的针剂和口服剂均不含有毒的巴豆油成份。毒性研究表明无论针剂或口服剂毒性均小,小鼠肌注其醇提取物,其LD50为49g/kg,灌胃LD50为224g/kg。
采用简便的TLC分析法对巴豆蒸制液提取物进行分析(其含量相当生药的0.5%,样品取提物适量溶于氯仿中,薄层色谱条件,用青岛海洋化工厂产硅胶G薄层20×5cm,室温干燥备用,展开剂为氯仿,显色剂为香草醛一浓硫酸,105℃加热10分钟显色),结果表明提取物中有10个组份。口服液中含两个D类成份。
采用气相色谱-质谱(GLC-MS)法进行组分分离及各种成份的化学结构的研究,结果表明从中可分离鉴定出24个化合物。
测试条件:
Finngan Mat212型质谱仪,分辨率500,电子能量70eV,发射电流1mA,离子源温度250℃;
SP3700型色谱仪,汽化220℃,OV-101玻璃毛细管柱(22m)、程序升温60~240℃,升温速率2℃/min,载气He,柱前压0.5kg/cm2,载气平均线速率12cm/s。
分析出的化合物包括烃、醛、酮、呋喃、醇及长链脂肪醇酯类六类共24个化合物。可以证明有效抗癌成份为总生物碱。但究竟哪个成份具有抗癌活性,有待进一步研究。
本发明的制备方法工艺简单,成本低,无污染,本发明的药理临床证明对多种癌症有效,尤其是胃癌。用本发明治疗晚期胃癌(病灶未切除者)81例,安全缓解7例,部分缓解20例,缓解率为33.3%,稳定32例,总有效率为72.8%,胃癌手术后治疗情况:一、胃断端未见癌细胞者31例5年生存率58.1%,10年生存率32.3%,其对照组86例(单纯手术切除或术后应用化疗及其他抗癌药物治疗者),5年生存率5%,86例病人无一例存活10年以上。二、胃断端有癌细胞浸润者治疗组16例,2年生存率81.3%,5年生存率18.8%,10年生存率12.5%,对照组14例(手术后应用化疗或其他抗癌药物治疗者),2年生存率14.3%,14例病人无一例存活2年以上。
应用本发明治疗甲状腺癌11例,8例肿瘤消失(其中6例未再复发),2例肿瘤缩小在一半以上,1例恶化。
实施例一
将巴豆研制成细粉,称取1.6公斤,加水7000毫升,在常压下蒸馏液3500毫升,在蒸馏液中加20~40%(体积比)的乙酸乙酯进行提取,共提取3次,回收乙酸乙酯得浸膏,再加入适量吐温-80,搅匀,加注射用水至足量,摇匀,反复过滤,分装于已处理好的干净安瓿中,封口、高压灭菌、灯检、印字。包装即得临床用肌注针剂,药物含量10~20mg/ml。
实施例二
称取巴豆粉10kg,粉碎后置渗滤桶内,然后加入石油醚浸泡48小时,放出滤液回收溶剂得巴豆油。将回收的溶剂再倒入桶内,反复渗滤三次,共得巴豆油4kg(收率40%);残渣倾出置透风处挥干,得脱脂巴豆粉约6kg(收率约60%)。将上述脱脂巴豆粉6kg装入渗滤桶内,加入酒精溶剂浸泡48小时,然后放出滤液,得棕黄色液体,回收溶剂得棕褐色浸膏。将回收之溶剂再倒入渗滤桶内,这样反复渗滤至溶剂无色为止,回收浓缩共得浸膏680g,收率按生药计约为4.1%。将上述浸膏溶解于水,再加入氯仿进行再脱脂四次,回收氯仿得巴豆残油46g,水溶液加热浓缩,得较纯净的浸膏156g。
将上述提取物156克,加入热水1000ml,搅拌使之溶解、过滤、即得口服剂原液。经加水稀释即可配制成临床用口服剂。
Claims (3)
1、一种巴豆抗癌药的制备方法,其特征在于该方法是由下列步骤组成:
(1)将巴豆粉碎,置容器中在水中常压蒸制;
(2)取蒸制液,加入20~40%(体积比)的乙酸乙酯提取至少二次;
(3)回收溶剂得浸膏,再加入助溶剂至搅拌均匀;
(4)加注射用水、摇匀、过滤、得无色透明溶液,即可用于配制注射用针剂。
2、根据权利要求1,其特征在于所说的助溶剂为吐温-80。
3、一种制备巴豆抗癌药的方法,其特征在于该方法是由下列步骤组成:
(1)将巴豆粉碎,置于石油醚有机溶剂中浸泡24~72小时,过滤,干燥得脱脂巴豆粉;
(2)将脱脂巴豆粉置于乙醇中浸泡24~72小时,过滤,得棕黄色溶液;
(3)回收溶剂,得棕黄色浸膏;
(4)将上述浸膏溶于水,过滤,再加入氯仿,使之充分混合,分离出水溶液,经加热浓缩,得纯净的巴豆浸膏;
(5)将上述浸膏溶解于水,制成水溶液,过滤,即可用于配制口服剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 89107860 CN1025908C (zh) | 1989-10-18 | 1989-10-18 | 巴豆抗癌药的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 89107860 CN1025908C (zh) | 1989-10-18 | 1989-10-18 | 巴豆抗癌药的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1050990A CN1050990A (zh) | 1991-05-01 |
CN1025908C true CN1025908C (zh) | 1994-09-14 |
Family
ID=4857366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 89107860 Expired - Fee Related CN1025908C (zh) | 1989-10-18 | 1989-10-18 | 巴豆抗癌药的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1025908C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1872066B (zh) * | 2005-06-03 | 2012-09-19 | 中国人民解放军军事医学科学院毒物药物研究所 | 巴豆根、茎、叶提取物,其抗炎镇痛有效成分和它们的用途 |
CN105176673A (zh) * | 2015-10-22 | 2015-12-23 | 河南行知专利服务有限公司 | 一种利用离子液体提取巴豆中脂肪油的方法 |
-
1989
- 1989-10-18 CN CN 89107860 patent/CN1025908C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1050990A (zh) | 1991-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5589182A (en) | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression | |
Pandey et al. | Saussurea costus: Botanical, chemical and pharmacological review of an ayurvedic medicinal plant | |
KR100239879B1 (ko) | 간암 예방 및 치료용 생약제 | |
US4767626A (en) | Remedy for anemia and arthritis | |
JPH0393725A (ja) | 新規抗癌剤 | |
US3136693A (en) | Therapeutic compositions and process for obtaining the same | |
CN1025908C (zh) | 巴豆抗癌药的制备方法 | |
CN115444893B (zh) | 一种降尿酸活性物质组合物及其应用 | |
CN104374890B (zh) | 一种苦丁茶冬青提取物 | |
CN109223739B (zh) | 一种组合物及其制备方法和应用 | |
CN1488355A (zh) | 芒果叶总苷止咳中药制剂及其生产方法 | |
CN102093380B (zh) | 环淫羊藿素苷元及其制备方法和应用 | |
CN102858359A (zh) | 一种含有醇溶性且非水溶性甘草提取物的药物组合物,及其药物制剂、制药用途、治疗方法和制备方法 | |
CN1923191B (zh) | 二氢黄酮类化合物在制备治疗心血管疾病药物中的应用 | |
JPH0267301A (ja) | 多糖類,その単離法および該多糖類を含む薬剤組成物 | |
CN1052412C (zh) | 治疗癌症的中药注射液及其制备方法 | |
JPS60255727A (ja) | 制癌剤 | |
KR100200182B1 (ko) | 황기 유래의 이소플라본을 함유하는 간기능 개선제 | |
CN116898897B (zh) | 补元气、耐缺氧、调理慢性疲劳的保元汤处方及制备方法 | |
CN108159218A (zh) | 一种具有抗肿瘤活性的二陈提取物及其制剂的制备方法 | |
KR920008160B1 (ko) | 암예방용 의약 조성물 | |
CN1022020C (zh) | 一种烟用添加剂及其制取方法 | |
CN1103227C (zh) | 龙牙楤木叶总皂甙在抗肿瘤药物制备中的用途 | |
CN112694441B (zh) | C20二萜生物碱、其制备及治疗疼痛相关疾病的用途 | |
CN101411780B (zh) | 一种具有抗恶性肿瘤作用的药物组合及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |